Related references
Note: Only part of the references are listed.Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Lisbeth V. Jacobsen et al.
CLINICAL PHARMACOKINETICS (2016)
Antidiabetic exendin-4 activates apoptotic pathway and inhibits growth of breast cancer cells
Guzin Fidan-Yaylali et al.
TUMOR BIOLOGY (2016)
The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism
Francesco Andreozzi et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Glucagon-like peptide-1 receptor agonists and risk of breast cancer
Shari D. Bolen et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Glucagon-like peptide-1 receptor agonists and risk of breast cancer
Shari D. Bolen et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
The association between diabetes and breast cancer stage at diagnosis: a population-based study
Lorraine L. Lipscombe et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
The AMP-activated protein kinase (AMPK) and cancer: Many faces of a metabolic regulator
Brandon Faubert et al.
CANCER LETTERS (2015)
Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies
Konstantinos K. Tsilidis et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies
Konstantinos K. Tsilidis et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
5′-AMP-activated Protein Kinase (AMPK) Supports the Growth of Aggressive Experimental Human Breast Cancer Tumors
Keith R. Laderoute et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
ABCG2/BCRP gene expression is related to epithelial-mesenchymal transition inducer genes in a papillary thyroid carcinoma cell line (TPC-1)
E. Mato et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2014)
The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells
Hagai Ligumsky et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
The structure and function of the glucagon-like peptide-1 receptor and its ligands
Dan Donnelly
BRITISH JOURNAL OF PHARMACOLOGY (2012)
SIGNIFICANTLY INCREASED RISK OF CANCER IN PATIENTS WITH DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Hiroshi Noto et al.
ENDOCRINE PRACTICE (2011)
Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters
M. Saxena et al.
CELL DEATH & DISEASE (2011)
ABCG2: A potential marker of stem cells and novel target in stern cell and cancer therapy
Xi-wei Ding et al.
LIFE SCIENCES (2010)
Liraglutide: A Once-Daily Incretin Mimetic for the Treatment of Type 2 Diabetes Mellitus
Joshua J. Neumiller et al.
ANNALS OF PHARMACOTHERAPY (2009)
Unraveling the Science of Incretin Biology
Michael A. Nauck
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2009)
Biology of incretins: GLP-1 and GIP
Laurie L. Baggio et al.
GASTROENTEROLOGY (2007)
GLP-1 receptor expression in human tumors and human normal tissues:: Potential for in vivo targeting
Meike Koerner et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system
PL Brubaker et al.
ENDOCRINOLOGY (2004)
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults
EE Calle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
